JAGUAR HEALTH, INC. Other Notes Payable, Current
JAGUAR HEALTH, INC. (JAGX) had Other Notes Payable, Current of $7.13 million as of 2020-03-31, per its 10-Q filed 2020-05-15.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Long-Term Debt, Current Maturities › Notes Payable, Current
us-gaap:OtherNotesPayableCurrent · last filed 2020-05-15
- 2020-03-31: Other Notes Payable, Current $7.13M.
- 2019-12-31: Other Notes Payable, Current $6.78M; Other Notes Payable, Current as first filed $6.78M.
- 2019-06-30: Other Notes Payable, Current $3.56M.
- 2018-12-31: Other Notes Payable, Current $4.85M.
| Period end | Other Notes Payable, Current | Other Notes Payable, Current as first filed |
|---|---|---|
| 2020-03-31 | $7.13M 10-Q · filed 2020-05-15 | |
| 2019-12-31 | $6.78M 10-Q · filed 2020-05-15 | $6.78M 10-K · filed 2020-04-03 |
| 2019-06-30 | $3.56M 10-Q · filed 2019-08-14 | |
| 2018-12-31 | $4.85M 10-K · filed 2020-04-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |